Erin Lavelle
First SEC filing: April 29, 2026 · Latest: June 11, 2026
Insider at
Insider transactions
Price change vs current quote, split-adjusted for corporate actions since the filing — not benchmarked, not annualized, not size-weighted
No open-market trades on record; showing all filings.
| Date | Ticker | Code | Shares | Price | Value | Owned after | Δ own | A/D | vs now |
|---|---|---|---|---|---|---|---|---|---|
| June 9, 2026 | JBIO | A | 34,843 | · | · | 34,843 Direct | · | Acquired | (price as of 2026-10-05) |
| April 30, 2026 | AVLN | A | 26,978 | · | · | 26,978 Direct | · | Acquired | (price as of 2026-10-05) |
| April 29, 2025 | JBIO | A | 23,017 | · | · | 23,017 Direct | · | Acquired | (price as of 2026-10-05) |
| June 8, 2023 | NGNE | A | 25,000 | · | · | 25,000 Direct | · | Acquired | (price as of 2026-10-05) |
| Oct. 31, 2022 | CLYM | A | 170,000 | · | · | 170,000 Direct | · | Acquired | (price as of 2026-10-05) |
| May 12, 2022 | NGNE | A | 25,000 | · | · | 25,000 Direct | · | Acquired | (price as of 2026-10-05) |
| Jan. 27, 2022 | CLYM | A | 170,000 | · | · | 170,000 Direct | · | Acquired | (price as of 2026-10-05) |
P = Open-market purchase · S = Sale · A = Grant/award · M = Option exercise · G = Gift · F = Tax withholding
Insider transactions are not a recommendation; sales are often driven by liquidity or tax reasons.
Derivative holdings (Form 4 Table II) Options, RSUs and convertible securities reported on Form 4 Table II.
| Date | Ticker | Security | Underlying | Exercise price | Expiration | Shares | A/D |
|---|---|---|---|---|---|---|---|
| June 9, 2026 | JBIO | Stock Option (Right to Buy) | Common Stock | $15.22 | June 8, 2036 | 34,843 | Acquired |
| April 30, 2026 | AVLN | Stock Option (Right to Buy) | Common Stock | $18.00 | April 28, 2036 | 26,978 | Acquired |
| April 29, 2025 | JBIO | Stock Option (Right to Buy) | Common Stock | $10.14 | April 29, 2035 | 23,017 | Acquired |
| June 8, 2023 | NGNE | Stock Option (Right to Buy) | Common Stock | $0.79 | June 7, 2033 | 25,000 | Acquired |
| Oct. 31, 2022 | CLYM | Stock Option (Right to Buy) | Common Stock | $3.27 | Oct. 30, 2032 | 170,000 | Acquired |
| May 12, 2022 | NGNE | Stock Option (Right to Buy) | Common Stock | $1.07 | May 11, 2032 | 25,000 | Acquired |
| Jan. 27, 2022 | CLYM | Stock Option (Right to Buy) | Common Stock | $8.21 | Jan. 26, 2032 | 170,000 | Acquired |
Exercise/conversion price is blank when not applicable (e.g. RSUs).
Initial ownership (Form 3) 5 holdings
Securities held when first becoming an insider, per SEC Form 3.
| Date | Ticker | Security | Shares | Ownership |
|---|---|---|---|---|
| April 29, 2026 | AVLN | Stock Option (right to buy) | 43,928 | Direct |
| May 1, 2025 | JBIO | Stock Option (Right to Buy) | 46,556 | Direct |
| May 1, 2025 | JBIO | Stock Option (Right to Buy) | 88,380 | Direct |
| Aug. 9, 2021 | CLYM | Stock Option (Right to Buy) | 235,190 | Direct |
| Aug. 9, 2021 | CLYM | Stock Option (Right to Buy) | 121,948 | Direct |
Compensation (DEF 14A)
Matched by name from proxy statements (DEF 14A) — verify against the filing.
| Fiscal year | Salary | Bonus | Stock awards | Option awards | Non-equity incentive | Pension change | Other | Total |
|---|---|---|---|---|---|---|---|---|
| 2022 | $465,750 | $209,588 | · | $1,371,917 | · | · | $12,200 | $2,059,455 |
| 2021 | $450,000 | $222,750 | · | $1,863,975 | · | · | $9,038 | $2,545,744 |
| 2020 | $112,500 | $50,625 | · | · | · | · | $2,250 | $163,375 |
Figures from the Summary Compensation Table of the company's proxy statement (DEF 14A). Compensation is not a recommendation.